Skip Navigation LinksHome > May 2013 - Volume 32 - Issue 5 > Cognitive Function and Neurodevelopmental Outcomes in HIV-in...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31827fb19d
HIV Reports

Cognitive Function and Neurodevelopmental Outcomes in HIV-infected Children Older Than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study

Puthanakit, Thanyawee MD*†; Ananworanich, Jintanat MD, PhD*‡§ †† ‡‡; Vonthanak, Saphonn MD, PhD; Kosalaraksa, Pope MD; Hansudewechakul, Rawiwan MD**; van der Lugt, Jasper MD, PhD*††; Kerr, Stephen J. PhD*‡‡; Kanjanavanit, Suparat MD§§; Ngampiyaskul, Chaiwat MD¶¶; Wongsawat, Jurai MD‖‖; Luesomboon, Wicharn MD***; Vibol, Ung MD†††; Pruksakaew, Kanchana BSc*; Suwarnlerk, Tulathip BNS*; Apornpong, Tanakorn MSc*; Ratanadilok, Kattiya PhD‡‡‡; Paul, Robert PhD§§§; Mofenson, Lynne M. MD¶¶¶; Fox, Lawrence MD, PhD‖‖‖; Valcour, Victor MD§ ****; Brouwers, Pim PhD††††; Ruxrungtham, Kiat MD, MSc*‡; on behalf of the PREDICT Study Group

Supplemental Author Material
Collapse Box


Background: We previously reported similar AIDS-free survival at 3 years in children who were >1 year old initiating antiretroviral therapy (ART) and randomized to early versus deferred ART in the Pediatric Randomized to Early versus Deferred Initiation in Cambodia and Thailand (PREDICT) study. We now report neurodevelopmental outcomes.

Methods: Two hundred eighty-four HIV-infected Thai and Cambodian children aged 1–12 years with CD4 counts between 15% and 24% and no AIDS-defining illness were randomized to initiate ART at enrollment (“early,” n = 139) or when CD4 count became <15% or a Centers for Disease Control (CDC) category C event developed (“deferred,” n = 145). All underwent age-appropriate neurodevelopment testing including Beery Visual Motor Integration, Purdue Pegboard, Color Trails and Child Behavioral Checklist. Thai children (n = 170) also completed Wechsler Intelligence Scale (intelligence quotient) and Stanford Binet Memory test. We compared week 144 measures by randomized group and to HIV-uninfected children (n = 319).

Results: At week 144, the median age was 9 years and 69 (48%) of the deferred arm children had initiated ART. The early arm had a higher CD4 (33% versus 24%, P < 0.001) and a greater percentage of children with viral suppression (91% versus 40%, P < 0.001). Neurodevelopmental scores did not differ by arm, and there were no differences in changes between arms across repeated assessments in time-varying multivariate models. HIV-infected children performed worse than uninfected children on intelligence quotient, Beery Visual Motor Integration, Binet memory and Child Behavioral Checklist.

Conclusions: In HIV-infected children surviving beyond 1 year of age without ART, neurodevelopmental outcomes were similar with ART initiation at CD4 15%–24% versus <15%, but both groups performed worse than HIV-uninfected children. The window of opportunity for a positive effect of ART initiation on neurodevelopment may remain in infancy.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.